News
The race to find an effective treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) for which no approved treatment exists,…
Read More
When Veracity Innovations LLC launched its new product at the 2017 American Society of Cataract and Refractive Surgery meeting in Los Angeles, the company was…
Read More
Stopping growth factors that create damage in the eye has proven lucrative. Lucentis (ranibizumab, Roche/Genentech) achieved sales of $1.8 billion in 2016 outside the US…
Read More
What’s Happening in the Month Ahead: September 2017 Ocugen, fresh off getting FDA orphan drug designation for OCU300-brimonidine to treat ocular graft rejection, will participate…
Read More
Last October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…
Read More
Strathspey Crown LLC has been granted the first patent on an intraocular lens (IOL) that includes a video camera, an LED display, and cellular, WiFi…
Read More
The annual meeting of the American Society of Retina Specialists featured four days of scientific sessions. Among the notable updates on key clinical trials from…
Read More
Candor, passion, realism, talent, flexibility, self awareness, humility, and focus are all qualities seed-stage benefactors look for in a start-up founder, a panel of fund…
Read More
In its second year OIS@ASRS has gone from a half-day to a full-day program that tomorrow will showcase 21 different presentations from companies in the…
Read More
A longstanding distribution agreement between Alimera Sciences and pSivida for the Iluvien intravitreal implant has been amended, much to the apparent benefit of both companies.…
Read More
In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…
Read More
FDA Shoots Down Ocular Therapeutix’s Dextenza NDA The Food and Drug Administration (FDA) denied approval of Ocular Therapeutix’s resubmitted New Drug Application (NDA) for its Dextenza…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")